Pharma Industry Concerned Over Drug Competition Bill.(Brief Article)

Chemical Market Reporter, October, 2001

THE PHARMACEUTICAL industry is concerned over a Senate committee's approval of legislation that would require brand-name drug companies to report to federal officials any time they pay a generic manufacturer to delay market introduction of a lower-priced copy. "We have concerns over the scope of the bill and the fact that it singles out one particular industry's agreements for scrutiny," says a spokeswoman for the Pharmaceutical Manufacturers of America (PhRMA).

"While we don't oppose the legislation, we will be working with both the House and the Senate to address these concerns as the bill moves forward," she says. The Senate Judiciary Committee on October 18 unanimously approved a bill that would require brand-name drugmakers to report to...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.